Skip to main content
Signal8

ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ZyVersa Therapeutics, Inc. logo

ZyVersa Therapeutics, Inc.

OTC:ZVSAHealthcare
$0.0001
Mkt Cap$810
EV-
Float8.09M
O/S8.1M
VOL100 sh
$ Vol$0
RVOL0.07×
Inst Own0.0%
Net Cash/Sh-
Dilution

ZyVersa Therapeutics, Inc. (ZVSA) dilution facts from SEC filings

Snapshot as of Mar 31, 2026, built from 28 SEC filings.

Shelf registration
S-3 filed Apr 4, 2025, effective Apr 9, 2025
Source: 10-K filed Mar 31, 2026
At-the-market (ATM) program
Yes, sales agreement dated Sep 16, 2024
Source: 10-K filed Mar 31, 2026
Warrants outstanding
10 warrant series recorded as outstanding
Most recent offering
PIPE, closed Feb 27, 2026
Source: 10-Q filed May 13, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro